Zimmer Biomet (ZBH) Valuation Check After Cautious Guidance At J.P. Morgan Healthcare Conference

Simply Wall St.01-18

Zimmer Biomet Holdings (ZBH) caught investor attention after cautious comments at the J.P. Morgan Healthcare Conference, where management signaled tempered expectations ahead of February earnings and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2604976075?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","is_english":true,"pubTime":"2026-01-18 21:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604976075","market":"hk","top_or_hot":-1,"title":"Zimmer Biomet (ZBH) Valuation Check After Cautious Guidance At J.P. Morgan Healthcare Conference","media":"Simply Wall St.","content":"<div>\n<p>Zimmer Biomet Holdings (ZBH) caught investor attention after cautious comments at the J.P. Morgan Healthcare Conference, where management signaled tempered expectations ahead of February earnings and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-zbh/zimmer-biomet-holdings/news/zimmer-biomet-zbh-valuation-check-after-cautious-guidance-at\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zimmer Biomet (ZBH) Valuation Check After Cautious Guidance At J.P. Morgan Healthcare Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZimmer Biomet (ZBH) Valuation Check After Cautious Guidance At J.P. Morgan Healthcare Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-18 21:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-zbh/zimmer-biomet-holdings/news/zimmer-biomet-zbh-valuation-check-after-cautious-guidance-at><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Zimmer Biomet Holdings (ZBH) caught investor attention after cautious comments at the J.P. Morgan Healthcare Conference, where management signaled tempered expectations ahead of February earnings and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-zbh/zimmer-biomet-holdings/news/zimmer-biomet-zbh-valuation-check-after-cautious-guidance-at\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XBI","symbol_name":"SPDR S&P Biotech ETF","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-zbh/zimmer-biomet-holdings/news/zimmer-biomet-zbh-valuation-check-after-cautious-guidance-at","article_id":"2604976075","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-zbh/zimmer-biomet-holdings/news/zimmer-biomet-zbh-valuation-check-after-cautious-guidance-at","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2604976075","pubTimestamp":1768742158,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Zimmer Biomet Holdings (ZBH) caught investor attention after cautious comments at the J.P. Morgan Healthcare Conference, where management signaled tempered expectations ahead of February earnings and highlighted planned changes for 2026.\nSee our latest analysis for Zimmer Biomet Holdings.\nThe cautious tone at the J.P. Morgan Healthcare Conference appears to have reinforced already weak momentum, with a 90 day share price return of 15.0% and a 1 year total shareholder return of 19.5% both...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"XBI":"SPDR S&P Biotech ETF","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","BK4585":"ETF&股票定投概念","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LABU":"三倍做多标普生物-Direxion","BK4534":"瑞士信贷持仓","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","HCSG":"Healthcare Svcs Group Inc","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","XLV":"健康照护类股ETF-SPDR","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","BK4082":"医疗保健设备","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","BK4504":"桥水持仓","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0557290698.USD":"施罗德环球可持续增长基金","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1548497426.USD":"安联环球人工智能AT Acc","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","ZBH":"齐默巴奥米特控股","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU0882574139.USD":"富达环球消费行业基金A ACC"},"translate_title":"在摩根大通医疗保健会议上提供谨慎指导后，Zimmer Biomet(ZBH)进行估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XBI":0.6,"HCSG":1.5,"XLV":1.5,"ZBH":1.5,"LABU":0.6},"content_text":"Zimmer Biomet Holdings (ZBH) caught investor attention after cautious comments at the J.P. Morgan Healthcare Conference, where management signaled tempered expectations ahead of February earnings and highlighted planned changes for 2026. See our latest analysis for Zimmer Biomet Holdings. The cautious tone at the J.P. Morgan Healthcare Conference appears to have reinforced already weak momentum, with a 90 day share price return of 15.0% and a 1 year total shareholder return of 19.5% both pointing to fading enthusiasm despite the current US$87.31 share price. Recent updates around the upcoming February 10 earnings call and the resignation of a named executive officer add to a period where investors are reassessing the balance between execution risk and potential rewards. If this kind of reset in expectations has you reviewing your watchlist, it could be a useful moment to compare Zimmer Biomet with other healthcare stocks that are catching investors' attention. With the shares down over the past year and the stock trading below some valuation estimates, it raises a simple question for you as an investor: Is Zimmer Biomet now trading at a discount, or is the market already pricing in future growth? AdvertisementMost Popular Narrative: 15.0% Undervalued The most followed valuation workup points to a fair value of about US$102.70 per share versus the last close at US$87.31, framing Zimmer Biomet as trading at a clear discount while still anchoring expectations in detailed earnings and margin assumptions.  The analysts have a consensus price target of $110.917 for Zimmer Biomet Holdings based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $138.0, and the most bearish reporting a price target of just $96.0.  Read the complete narrative. Curious what sits behind that valuation gap? The narrative leans on measured revenue growth, firmer margins and a future earnings multiple that is described in detail rather than casually assumed. Result: Fair Value of $102.70 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the narrative could be tested if pricing pressure and reimbursement headwinds persist, or if acquisitions and new robotics platforms take longer to deliver. Find out about the key risks to this Zimmer Biomet Holdings narrative.  Build Your Own Zimmer Biomet Holdings Narrative If you see the story differently, or simply prefer to weigh the numbers yourself, you can build a custom thesis in just a few minutes: Do it your way A great starting point for your Zimmer Biomet Holdings research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision. Looking for more investment ideas? If you are serious about sharpening your portfolio, do not stop at one company; use the screener to uncover fresh ideas that match your style.  Spot potential value candidates early by scouting these 873 undervalued stocks based on cash flows that the market may be overlooking based on their cash flow profiles. Ride powerful tech themes by checking out these 24 AI penny stocks that link artificial intelligence to real business models and financials. Target income-focused opportunities by scanning these 12 dividend stocks with yields > 3% that already offer yields above 3% on current prices.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Zimmer Biomet Holdings might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2604976075","isCrawlerRequest":true}